Bon Natural Life Limited
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBon Natural Life Ltd is a China-based producer of natural plant extracts and health food ingredients, with a shrinking revenue base and a recent move into the US market.
What they do
The company develops and manufactures natural plant-derived products, including food ingredients and nutritional supplements. Its operating subsidiaries are primarily in Xi'an, China, and it recently established a US-based entity, Bon Natural Life USA. The business also includes a tea essence subsidiary and a joint venture, Tea Essence Tech Hangzhou Co., Ltd.
Revenue drivers
- Plant extract products — Core product line, though specific segment revenue was not broken out in the provided excerpt; total revenue declined from $25.5M in 2021 to $18.7M in 2025.
- Health and nutritional products — Part of the overall product portfolio, contributing to the declining top line; no separate revenue figures available.
- Tea essence business (Tea Essence Limited) — A separate subsidiary and joint venture (Tea Essence Tech HangZhou Co., Ltd.) that adds product diversity but has not offset overall revenue declines.
Recent performance
For fiscal 2025 (year ended September 30, 2025), revenue was $18.7M, down from $23.8M in fiscal 2024 and well below the $29.9M peak in 2022. Net income swung to a loss of $2.0M in 2025, versus a near-breakeven $398,172 in 2024. Operating cash flow turned slightly positive at $141,115 in 2025 after -$7.7M in 2024. As of September 30, 2025, total assets were $85.2M, liabilities $27.2M, and cash was $6.3M.
Strategy
The company has been expanding through foreign subsidiaries, including the establishment of Bon Natural Life USA in fiscal 2025. It also acquired or formed entities like AppChem Health in June 2025 and has partnerships such as Tea Essence Tech HangZhou. Management's stated direction is to grow through new product development and market expansion, though specific investments and priorities were not detailed. The recent loss suggests cost pressures or investment spending ahead of revenue growth.
Risks
- Declining revenue trend — Revenue has fallen for three consecutive years, from $29.9M in 2022 to $18.7M in 2025, indicating persistent demand or competitive challenges.
- Profitability deterioration — Net income fell from $4.6M in 2023 to a $2.0M net loss in 2025, reflecting margin compression and possible impairment or one-time charges.
- Cash flow volatility — Operating cash flow swung from -$7.7M in 2024 to just +$141K in 2025, leaving limited internal funding for growth.
- Concentration in China — Operations are heavily based in Xi'an and other Chinese regions, exposing the company to local regulatory, economic, and geopolitical risks.
Outlook
Management did not provide explicit forward guidance in the excerpts. The company is likely focusing on stabilizing revenue through new markets like the US and new ventures such as AppChem Health. Given the recent net loss and thin cash position, the outlook depends on successful execution of expansion plans and cost control. Continuation of the multi-year revenue decline could signal further operational challenges.